Library / regulatory-reference
Botswana: Botswana Medicines Regulatory Authority (BoMRA)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
The Botswana Medicines Regulatory Authority, known as BoMRA, is Botswana's national regulator for medicines and related substances, established under the medicines and related substances law as the successor to the ministry's former drug regulatory unit.
Botswana imports most of its medicines, and the authority's registration and licensing work controls entry into a market that serves both the public health system and private retail.
How products enter the market
Medicines require registration after evaluation of quality, safety and efficacy, and entities handling manufacture, import, wholesale and retail are licensed and inspected.
Post-market work includes safety monitoring, quality surveillance and recalls.
Regional and international role
The authority participates in Southern African regulatory work-sharing, including the ZAZIBONA joint-assessment initiative, which lets smaller regulators share evaluation burdens.
Its transition from a ministry unit to an autonomous authority is a structural model followed elsewhere in the region.
Using this profile
The authority publishes guidelines, registers and announcements in English through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: BoMRA illustrates the corporatized successor: a ministry regulatory unit converted into an autonomous authority with its own licensing and enforcement powers.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.